BACKGROUND: The decrement in utility attributable to side effects from combination antiretroviral therapy (CART) is unknown and likely to influence clinical decisions regarding CART initiation and cost-effectiveness. OBJECTIVE: To quantify the decrement in utility attributable to side effects from CART. METHODS: We estimated SF-6D utilities (quality-of-life weights on a scale from 0.29 [worst possible health] to 1.00 [perfect health]) from SF-12 scores among patients with HIV in the Veterans Aging Cohort Study by using a published and validated conversion algorithm. We then compared utilities among patients who: 1) did not have bothersome symptoms while taking CART; 2) had bothersome symptoms that they thought might be due to CART; and 3) had bothersome symptoms that they were confident were due to CART; we controlled for other characteristics known to influence quality of life and stratified analyses by CD4 count. RESULTS: Among 1864 patients with available data, symptoms perceived to be attributable to CART were associated with a mean (95% confidence interval) decrement in utility of 0.06 (0.05, 0.08) points in univariate analyses and 0.08 (0.06, 0.10) in multivariable analyses, clinically significant differences that are comparable to utility decrements reported for partial impotence or mild angina. Other significant predictors of changes in SF-6D utilities were hazardous alcohol consumption, recent drug use, cigarette smoking, homelessness, and African American race (R(2) = 0.12). Stratifying by CD4 count, symptoms attributable to CART side effects decreased utility by 0.03 to 0.08 points. CONCLUSIONS: Symptoms perceived to be related to CART are associated with a substantial decrement in utility.
BACKGROUND: The decrement in utility attributable to side effects from combination antiretroviral therapy (CART) is unknown and likely to influence clinical decisions regarding CART initiation and cost-effectiveness. OBJECTIVE: To quantify the decrement in utility attributable to side effects from CART. METHODS: We estimated SF-6D utilities (quality-of-life weights on a scale from 0.29 [worst possible health] to 1.00 [perfect health]) from SF-12 scores among patients with HIV in the Veterans Aging Cohort Study by using a published and validated conversion algorithm. We then compared utilities among patients who: 1) did not have bothersome symptoms while taking CART; 2) had bothersome symptoms that they thought might be due to CART; and 3) had bothersome symptoms that they were confident were due to CART; we controlled for other characteristics known to influence quality of life and stratified analyses by CD4 count. RESULTS: Among 1864 patients with available data, symptoms perceived to be attributable to CART were associated with a mean (95% confidence interval) decrement in utility of 0.06 (0.05, 0.08) points in univariate analyses and 0.08 (0.06, 0.10) in multivariable analyses, clinically significant differences that are comparable to utility decrements reported for partial impotence or mild angina. Other significant predictors of changes in SF-6D utilities were hazardous alcohol consumption, recent drug use, cigarette smoking, homelessness, and African American race (R(2) = 0.12). Stratifying by CD4 count, symptoms attributable to CART side effects decreased utility by 0.03 to 0.08 points. CONCLUSIONS: Symptoms perceived to be related to CART are associated with a substantial decrement in utility.
Authors: A C Justice; W Holmes; A L Gifford; L Rabeneck; R Zackin; G Sinclair; S Weissman; J Neidig; C Marcus; M Chesney; S E Cohn; A W Wu Journal: J Clin Epidemiol Date: 2001-12 Impact factor: 6.437
Authors: Paul M Coplan; John R Cook; George W Carides; Joseph F Heyse; Albert W Wu; Scott M Hammer; Bach-Yen Nguyen; Anne R Meibohm; Mark J DiNubile Journal: Clin Infect Dis Date: 2004-07-19 Impact factor: 9.079
Authors: Chenglong Liu; David Ostrow; Roger Detels; Zheng Hu; Lisette Johnson; Lawrence Kingsley; Lisa P Jacobson Journal: Qual Life Res Date: 2006-08 Impact factor: 3.440
Authors: Claudia M Nader; Joel Tsevat; Amy C Justice; Joseph M Mrus; Forrest Levin; Michael J Kozal; Kristin Mattocks; Steven Farber; Michelle Rogers; Joseph Erdos; Cynthia Brandt; Ian Kudel; Ronald Braithwaite Journal: AIDS Patient Care STDS Date: 2009-07 Impact factor: 5.078
Authors: Angela A Aidala; Michael G Wilson; Virginia Shubert; David Gogolishvili; Jason Globerman; Sergio Rueda; Anne K Bozack; Maria Caban; Sean B Rourke Journal: Am J Public Health Date: 2015-11-12 Impact factor: 9.308
Authors: Bruce R Schackman; David W Haas; Jessica E Becker; Bethany K Berkowitz; Paul E Sax; Eric S Daar; Heather J Ribaudo; Kenneth A Freedberg Journal: Antivir Ther Date: 2012-12-21
Authors: Bruce R Schackman; David W Haas; Sanghee S Park; X Cynthia Li; Kenneth A Freedberg Journal: Pharmacogenomics Date: 2015-11-26 Impact factor: 2.533
Authors: R Scott Braithwaite; Mark S Roberts; Chung Chou H Chang; Matthew Bidwell Goetz; Cynthia L Gibert; Maria C Rodriguez-Barradas; Steven Shechter; Andrew Schaefer; Kimberly Nucifora; Robert Koppenhaver; Amy C Justice Journal: Ann Intern Med Date: 2008-02-05 Impact factor: 25.391
Authors: R Scott Braithwaite; Kimberly A Nucifora; Constantin T Yiannoutsos; Beverly Musick; Sylvester Kimaiyo; Lameck Diero; Melanie C Bacon; Kara Wools-Kaloustian Journal: J Int AIDS Soc Date: 2011-07-30 Impact factor: 5.396
Authors: Anik R Patel; Jason Kessler; R Scott Braithwaite; Kimberly A Nucifora; Harsha Thirumurthy; Qinlian Zhou; Richard T Lester; Carlo A Marra Journal: Medicine (Baltimore) Date: 2017-02 Impact factor: 1.889